| 1 |
35013615 | Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. | 2022 Jan |
1 |
| 2 |
34011528 | Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer. | 2021 Jul |
3 |
| 3 |
34945784 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. | 2021 Dec 6 |
1 |
| 4 |
32616555 | A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. | 2020 Jul |
2 |
| 5 |
30610805 | The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide. | 2018 Nov-Dec |
2 |
| 6 |
28893901 | Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. | 2017 Nov 15 |
1 |
| 7 |
25428917 | PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. | 2015 Jan 1 |
1 |